We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Envista (NVST) Q4 Earnings Miss Estimates, Margins Down
Read MoreHide Full Article
Envista Holdings Corporation (NVST - Free Report) reported fourth-quarter 2023 adjusted earnings per share (EPS) of 29 cents, down 44.2% year over year. The bottom line missed the Zacks Consensus Estimate by 12.1%.
The adjustments include charges and benefits related to the amortization of acquired intangible assets, goodwill and intangible asset impairment, among others.
The company’s loss from continuing operations was $1.27 in the quarter compared with the year-ago quarter’s EPS of 45 cents.
For the full year, adjusted earnings were $1.53 per share, reflecting a 21.2% fall from the year-ago period. It also missed the Zacks Consensus Estimate by 3.2%.
Revenues in Detail
Revenues totaled $645.6 million in the reported quarter, down 2.3% year over year. However, the metric topped the Zacks Consensus Estimate by 2.3%.
Total revenues for 2023 were $2.57 billion, dropping 0.1% from the year-ago period’s levels. The figure beat the Zacks Consensus Estimate by 0.8%.
Segments in Detail
In the fourth quarter, Speciality Products & Technologies totaled $415.9 million, up 4.4%. Within the segment, Envista’s Orthodontic business rose nearly 15%, with Spark continuing to outperform.
Revenues in the Equipment & Consumables segment fell 12.5% year over year to $229.7 million in the quarter under review. The downside was primarily due to the timing of orders in the North American distribution channel.
Operational Update
Gross profit in the reported quarter fell 8.3% year over year to $335.9 million. Gross margin contracted 339 basis points (bps) to 52%.
Selling, general and administrative expenses were up 2.6% year over year to $260.2 million. Research and development expenses fell 17.9% year over year to $20.2 million.
Envista Holdings Corporation Price, Consensus and EPS Surprise
Operating profit of $55.5 million fell 36.9% year over year. The operating margin contracted 472 bps to 8.6%.
Financial Update
Envista ended 2023 with cash and cash equivalents of $940 million compared with $606.9 million at the end of 2022. Total long-term debt was $1.39 billion at the end of 2023 compared with $870.7 million at the end of 2022.
Net cash provided by operating activities at the end of 2023 was $275.7 million compared with $182.7 million a year ago.
2024 Guidance
Envista provided 2024 guidance.
For the full year 2024, Envista expects core sales to grow by low-single digits. The Zacks Consensus Estimate for 2024 revenues is pegged at $2.60 billion.
Adjusted EBITDA margins are expected to be 16-17%.
Our Take
Envista ended fourth-quarter 2023 on a mixed note with better-than-expected revenues and earnings miss. Within the Equipment & Consumables segment, Envista’s Orthodontic business grew as Spark continues to outperform. The Bracket & Wires business delivered mid-single-digit growth, with emerging markets performing especially well. The company’s IOS business registered strong growth in the fourth quarter, driven by strong unit demand and a stabilizing price environment.
However, revenues in the Equipment & Consumables segment fell due to the timing of orders in the North American distribution channel. The contraction of both margins looks discouraging, too.
Zacks Rank and Key Picks
Envista currently carries Zacks Rank #5 (Strong Sell).
Some better-ranked stocks from the broader medical space are Stryker Corporation (SYK - Free Report) , Boston Scientific (BSX - Free Report) and Cardinal Health (CAH - Free Report) .
Stryker, carrying a Zacks Rank #2 (Buy), reported a fourth-quarter 2023 adjusted EPS of $3.46, beating the Zacks Consensus Estimate by 5.8%. Revenues of $5.8 billion outpaced the consensus estimate by 3.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker has an estimated earnings growth rate of 11.5% for 2025 compared with the S&P 500’s 9.9%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 5.1%.
Boston Scientific, carrying a Zacks Rank #2, reported a fourth-quarter 2024 adjusted EPS of 55 cents, which beat the Zacks Consensus Estimate by 7.8%. Revenues of $3.73 billion outpaced the Zacks Consensus Estimate by 3.8%.
BSX has a long-term estimated earnings growth rate of 12.7%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 7.4%.
Cardinal Health reported second-quarter fiscal 2024 adjusted earnings of $1.82, beating the Zacks Consensus Estimate by 16.7%. Revenues of $57.45 billion increased 11.6% on a year-over-year basis and topped the Zacks Consensus Estimate by 1.1%.
CAH has a long-term estimated earnings growth rate of 15.3% compared with the industry’s 11.8% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Envista (NVST) Q4 Earnings Miss Estimates, Margins Down
Envista Holdings Corporation (NVST - Free Report) reported fourth-quarter 2023 adjusted earnings per share (EPS) of 29 cents, down 44.2% year over year. The bottom line missed the Zacks Consensus Estimate by 12.1%.
The adjustments include charges and benefits related to the amortization of acquired intangible assets, goodwill and intangible asset impairment, among others.
The company’s loss from continuing operations was $1.27 in the quarter compared with the year-ago quarter’s EPS of 45 cents.
For the full year, adjusted earnings were $1.53 per share, reflecting a 21.2% fall from the year-ago period. It also missed the Zacks Consensus Estimate by 3.2%.
Revenues in Detail
Revenues totaled $645.6 million in the reported quarter, down 2.3% year over year. However, the metric topped the Zacks Consensus Estimate by 2.3%.
Total revenues for 2023 were $2.57 billion, dropping 0.1% from the year-ago period’s levels. The figure beat the Zacks Consensus Estimate by 0.8%.
Segments in Detail
In the fourth quarter, Speciality Products & Technologies totaled $415.9 million, up 4.4%. Within the segment, Envista’s Orthodontic business rose nearly 15%, with Spark continuing to outperform.
Revenues in the Equipment & Consumables segment fell 12.5% year over year to $229.7 million in the quarter under review. The downside was primarily due to the timing of orders in the North American distribution channel.
Operational Update
Gross profit in the reported quarter fell 8.3% year over year to $335.9 million. Gross margin contracted 339 basis points (bps) to 52%.
Selling, general and administrative expenses were up 2.6% year over year to $260.2 million. Research and development expenses fell 17.9% year over year to $20.2 million.
Envista Holdings Corporation Price, Consensus and EPS Surprise
Envista Holdings Corporation price-consensus-eps-surprise-chart | Envista Holdings Corporation Quote
Operating profit of $55.5 million fell 36.9% year over year. The operating margin contracted 472 bps to 8.6%.
Financial Update
Envista ended 2023 with cash and cash equivalents of $940 million compared with $606.9 million at the end of 2022. Total long-term debt was $1.39 billion at the end of 2023 compared with $870.7 million at the end of 2022.
Net cash provided by operating activities at the end of 2023 was $275.7 million compared with $182.7 million a year ago.
2024 Guidance
Envista provided 2024 guidance.
For the full year 2024, Envista expects core sales to grow by low-single digits. The Zacks Consensus Estimate for 2024 revenues is pegged at $2.60 billion.
Adjusted EBITDA margins are expected to be 16-17%.
Our Take
Envista ended fourth-quarter 2023 on a mixed note with better-than-expected revenues and earnings miss. Within the Equipment & Consumables segment, Envista’s Orthodontic business grew as Spark continues to outperform. The Bracket & Wires business delivered mid-single-digit growth, with emerging markets performing especially well. The company’s IOS business registered strong growth in the fourth quarter, driven by strong unit demand and a stabilizing price environment.
However, revenues in the Equipment & Consumables segment fell due to the timing of orders in the North American distribution channel. The contraction of both margins looks discouraging, too.
Zacks Rank and Key Picks
Envista currently carries Zacks Rank #5 (Strong Sell).
Some better-ranked stocks from the broader medical space are Stryker Corporation (SYK - Free Report) , Boston Scientific (BSX - Free Report) and Cardinal Health (CAH - Free Report) .
Stryker, carrying a Zacks Rank #2 (Buy), reported a fourth-quarter 2023 adjusted EPS of $3.46, beating the Zacks Consensus Estimate by 5.8%. Revenues of $5.8 billion outpaced the consensus estimate by 3.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker has an estimated earnings growth rate of 11.5% for 2025 compared with the S&P 500’s 9.9%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 5.1%.
Boston Scientific, carrying a Zacks Rank #2, reported a fourth-quarter 2024 adjusted EPS of 55 cents, which beat the Zacks Consensus Estimate by 7.8%. Revenues of $3.73 billion outpaced the Zacks Consensus Estimate by 3.8%.
BSX has a long-term estimated earnings growth rate of 12.7%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 7.4%.
Cardinal Health reported second-quarter fiscal 2024 adjusted earnings of $1.82, beating the Zacks Consensus Estimate by 16.7%. Revenues of $57.45 billion increased 11.6% on a year-over-year basis and topped the Zacks Consensus Estimate by 1.1%.
CAH has a long-term estimated earnings growth rate of 15.3% compared with the industry’s 11.8% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.6%.